European Commission Finds “Pay For Delay” Deals On The Decline In Europe But Pharma Sector Antitrust Scrutiny Continues


On July 6, 2011 the European Commission (Commission) published the

results of its second monitoring exercise of patent settlements in

the pharmaceutical sector (Second Monitoring Report). The Commission notes “with satisfaction” that there is a continued decline in the number of patent settlements it considers to be “potentially problematic” under EU antitrust law. The absolute number of patent settlements increased in relative terms in 2010, showing that the Commission does not prevent companies from settling patent disputes within the boundaries of EU antitrust law. However, ongoing probes at EU and Member State level indicate that the sector will continue to be under the antitrust spotlight.


Companies operating in the EU pharmaceutical sector will be familiar with the Commission’s sustained interest in their business which reached a highwater mark with an 18-month sector inquiry and final report in July 2009 (Final Report). However, the sector inquiry provided only a limited indication of which patent settlements would invite antitrust scrutiny in the EU. In relation to patent settlements, the Final Report stated:

“Agreements that are designed to keep competitors out of the market may also run afoul of [EU] competition law. Settlement agreements that limit generic entry and include a value transfer from an originator company to one or more generic companies are an example of such potentially anticompetitive agreements, in particular where the motive of the agreement is the sharing of profits via payments from originator to generic companies to the detriment of patients and public health budgets.

Please see full Alert below for further information.

LOADING PDF: If there are any problems, click here to download the file.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© King & Spalding | Attorney Advertising

Written by:


King & Spalding on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.

Already signed up? Log in here

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.